Your browser is no longer supported. Please, upgrade your browser.
ATNM Actinium Pharmaceuticals, Inc. monthly Stock Chart
ATNM [AMEX]
Actinium Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own1.55% Shs Outstand15.43M Perf Week-0.80%
Market Cap153.75M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float13.38M Perf Month4.48%
Income-20.40M PEG- EPS next Q-0.37 Inst Own22.20% Short Float4.90% Perf Quarter31.18%
Sales- P/S- EPS this Y34.20% Inst Trans-11.21% Short Ratio1.86 Perf Half Y79.50%
Book/sh2.94 P/B3.81 EPS next Y23.70% ROA-64.60% Target Price- Perf Year63.60%
Cash/sh3.51 P/C3.19 EPS next 5Y- ROE-78.00% 52W Range4.71 - 19.47 Perf YTD71.34%
Dividend- P/FCF- EPS past 5Y30.50% ROI- 52W High-42.53% Beta1.20
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low137.58% ATR0.68
Employees25 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)51.56 Volatility3.78% 6.16%
OptionableYes Debt/Eq0.00 EPS Q/Q70.40% Profit Margin- Rel Volume0.74 Prev Close10.89
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume352.52K Price11.19
Recom1.80 SMA200.19% SMA505.07% SMA20021.30% Volume260,655 Change2.75%
Nov-05-20Initiated Alliance Global Partners Buy $25
Dec-06-17Initiated B. Riley FBR, Inc. Buy $2.75
Oct-23-17Resumed ROTH Capital Buy $6
Sep-14-17Initiated Maxim Group Buy $3
Aug-25-16Initiated ROTH Capital Buy $5
Feb-29-16Initiated H.C. Wainwright Buy $8
Oct-15-15Initiated FBR Capital Outperform $12
Oct-01-14Initiated MLV & Co Buy $16
Jul-22-14Initiated Canaccord Genuity Buy $16
Nov-23-20 07:00AM  
Nov-20-20 05:45PM  
Nov-19-20 07:30AM  
Nov-16-20 07:00AM  
Nov-13-20 05:45PM  
Nov-11-20 08:00AM  
Nov-04-20 12:21PM  
12:13PM  
12:00PM  
Oct-29-20 11:30AM  
Oct-28-20 07:00AM  
Oct-22-20 05:45PM  
Oct-21-20 08:04AM  
07:00AM  
Oct-14-20 07:00AM  
Oct-09-20 06:37AM  
Oct-08-20 05:45PM  
Oct-06-20 07:00AM  
Oct-02-20 05:45PM  
Sep-23-20 07:00AM  
Sep-14-20 07:00AM  
Sep-10-20 07:00AM  
Aug-31-20 06:05PM  
Aug-28-20 11:30AM  
Aug-26-20 08:48AM  
Aug-12-20 11:30AM  
Aug-10-20 02:30PM  
12:00PM  
Aug-04-20 05:45PM  
Aug-03-20 11:54AM  
Jul-28-20 05:50PM  
Jul-27-20 11:30AM  
Jul-23-20 12:00PM  
Jul-21-20 08:57AM  
Jul-20-20 10:32AM  
Jul-15-20 07:03AM  
Jul-09-20 11:30AM  
Jul-08-20 09:05AM  
Jun-19-20 05:15PM  
Jun-17-20 11:30AM  
Jun-16-20 11:30PM  
04:01PM  
Jun-15-20 11:29PM  
Jun-12-20 08:43AM  
Jun-09-20 08:47AM  
Jun-04-20 09:45PM  
09:42AM  
Jun-03-20 09:53AM  
Apr-24-20 05:15PM  
Apr-21-20 11:35PM  
04:01PM  
Apr-16-20 07:00AM  
Apr-12-20 09:02AM  
Mar-06-20 10:56AM  
Mar-05-20 07:30AM  
Feb-26-20 07:33AM  
Feb-25-20 09:33AM  
Feb-21-20 07:30AM  
Feb-13-20 08:03AM  
Feb-05-20 05:50PM  
08:03AM  
Jan-30-20 05:45PM  
Jan-13-20 12:00PM  
07:15AM  
07:03AM  
Jan-07-20 07:03AM  
Jan-03-20 11:30AM  
Jan-02-20 09:29AM  
Dec-22-19 05:08PM  
Dec-09-19 06:10AM  
06:00AM  
Dec-07-19 08:35AM  
Dec-01-19 09:30AM  
Nov-20-19 09:00AM  
Nov-07-19 04:05PM  
Nov-06-19 09:15AM  
09:00AM  
Oct-28-19 08:20AM  
Oct-15-19 10:48AM  
Sep-30-19 08:00AM  
Sep-23-19 08:00AM  
Sep-16-19 08:00AM  
Jul-23-19 08:00AM  
Jul-17-19 12:56PM  
Jul-11-19 08:00AM  
Jun-26-19 08:00AM  
Jun-25-19 08:00AM  
Jun-20-19 08:00AM  
Jun-04-19 08:00AM  
May-24-19 01:40PM  
May-16-19 08:00AM  
May-07-19 08:00AM  
Apr-18-19 09:00AM  
Apr-17-19 04:01PM  
Apr-08-19 08:00AM  
Apr-04-19 09:57AM  
Apr-03-19 09:16AM  
08:00AM  
Apr-01-19 09:00AM  
Mar-29-19 08:00AM  
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.